Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Monoclonal Antibodies In Veterinary Health Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The monoclonal antibodies in veterinary health market size has experienced rapid expansion in recent years. This market is projected to increase from $0.92 billion in 2025 to $1.06 billion in 2026, at a compound annual growth rate (CAGR) of 15.2%. The historical growth can be attributed to the rising prevalence of canine cancers, the increasing incidence of autoimmune disorders in pets, the limited availability of targeted therapies, the expansion of veterinary hospitals, and a greater awareness of advanced veterinary treatments.
The monoclonal antibodies in veterinary health market is expected to witness substantial expansion over the next few years. It is projected to grow to $1.85 billion by 2030, achieving a compound annual growth rate (CAGR) of 14.8%. This growth during the forecast period can be attributed to several factors, including technological advancements in mAb engineering, a rising adoption of species-specific therapies, increased investment in veterinary oncology and dermatology, the expansion of personalized veterinary medicine, and the strengthening of the global veterinary healthcare infrastructure. Significant trends anticipated in this period encompass the increase in monoclonal antibody-based treatments for canine cancer, a growing utilization of mabs for autoimmune disorders in dogs, broader application in veterinary dermatology, a surge in the adoption of targeted pain management therapies, and the creation of species-specific antibody treatments for cats, horses, and livestock.
Get A Free Sample Report With In-Depth Market Insights:
Monoclonal Antibodies In Veterinary Health Market Demand Drivers Opening New Revenue Streams
The increasing occurrence of animal diseases is projected to drive the expansion of the monoclonal antibodies in veterinary health market in the future. This escalation in animal disease cases stems from more intensive farming methods, heightening the risk of infectious disease propagation, alongside climate change, which broadens the habitats of disease-carrying agents like ticks and mosquitoes. Monoclonal antibodies prove very effective in addressing animal ailments because they precisely target particular pathogens or proteins central to disease mechanisms, providing accurate and potent therapeutic solutions. For example, a report released by GOV.UK, a UK-based government website, in June 2024, revealed that from April 2023 to March 2024, the number of animals slaughtered due to TB incidents increased by 5% in England, reaching 21,298, and by 17% in Wales, to 11,197. Consequently, the escalating animal disease incidences are clearly fueling the growth of the monoclonal antibodies in veterinary health market.
Monoclonal Antibodies In Veterinary Health Market Segment Landscape And Growth Outlook
The monoclonal antibodies in veterinary health market covered in this report is segmented –
1) By Product: Monoclonal Antibodies (mAbs), Glucocorticoids, Antihistamines, Immunosuppressants, Other Products
2) By Animal Type: Dogs, Cats, Horses, Livestock, Other Animals
3) By Indication: Allergic Skin Disease, Autoimmune Disorders, Infectious Diseases, Cancer Or Tumor Therapy, Other Indications
4) By Route Of Administration: Injectable, Oral, Topical
5) By Distribution Channel: Veterinary Clinics, Specialized Animal Hospitals, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Lokivetmab, Felvetmab, Investigational Monoclonal Antibodies, Equine-specific mAbs
2) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone
3) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine
4) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil
5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics
Monoclonal Antibodies In Veterinary Health Market Trends Powering Strategic Industry Growth
Major companies operating within the monoclonal antibodies in veterinary health market are concentrating on creating innovative veterinary therapeutic solutions, such as anti-NGF monoclonal antibody treatment, to tackle ailments like chronic pain and inflammation in animals. Anti-NGF monoclonal antibody treatment refers to a therapeutic approach that involves targeting and inhibiting nerve growth factor (NGF) to alleviate pain and inflammation in animals experiencing chronic pain conditions. For instance, in May 2023, Zoetis, a US-based animal health company, gained FDA approvals for Librela (bedinvetmab injection), which is the initial monoclonal antibody treatment for controlling pain associated with osteoarthritis (OA) in dogs, administered as a once-monthly injection. Additionally, they secured approval for Apoquel Chewable, the first chewable medication specifically designed for managing allergic itch and inflammation in dogs aged one year or older. Librela itself is a monoclonal antibody engineered to target and inhibit nerve growth factor (NGF). By blocking NGF, Librela helps prevent these pain signals from reaching the brain, consequently reducing the sensation of pain in dogs afflicted with osteoarthritis. Librela represents a notable advancement in veterinary pain management, introducing a novel method for addressing chronic pain in dogs.
Monoclonal Antibodies In Veterinary Health Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the monoclonal antibodies in veterinary health market are Zoetis Inc, Boehringer Ingelheim International GmbH, MSD Animal Health, Elanco Animal Health Incorporated, Heska Corporation, Ceva Santé Animale S.A., Biogénesis Bagó S.A., PetMedix Ltd, Merck & Co Inc, Virbac SA, Kindred Biosciences Inc, Dechra Pharmaceuticals, Vetigenics, Akston Biosciences Corporation, MabGenesis Inc, IDEXX Laboratories Inc, Nexvet Biopharma, Epitopix LLC, Indian Immunologicals Ltd, Vetoquinol, Phibro Animal Health, Norbrook Laboratories, AnimalCare, Eco Animal Health, Venkys, Hester Biosciences Limited, ImmuCell
View The Full Monoclonal Antibodies In Veterinary Health Market Report:
Monoclonal Antibodies In Veterinary Health Market Geographic Distribution And Regional Opportunities
North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
